Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
ConditionDengue Fever
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age7+
SponsorGeorge Washington University
About this trial
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male or female, aged >7 years
Willingness to receive intravenous medication and be willing to adhere to the medication regimen
Disqualifiers
Pregnancy or lactation
Children in Care of the state
Patients who are unlikely to survive 48 hours
Unstable cardiac disease or arrhythmia at baseline
Trial design
Treatments tested in this trial
- Zanamivir
- Placebo
Treatment groups
74 Participants
are divided into 2 treatment groupsSponsors and collaborators
George Washington University
Lead sponsor
Naval Medical Research Center
Collaborator
Clinica de la Costa
Collaborator
Global Disease Research
Collaborator
Universidad Libre de Barranquilla
Collaborator
Source ClinicalTrials.gov